L. Albiges, N. Tannir, M. Burotto, D. McDermott, E. Plimack, P. Barthélémy, C. Porta, T. Powles, F. Donskov, S. George, C. Kollmannsberger, H. Gurney, M. Grimm, Y. Tomita, D. Castellano, B. Rini, T. Choueiri, S. Shally Saggi, M. Mchenry, R. Motzer
{"title":"Nivolumab + ipilimumab (N + I) vs sunitinib (S)在晚期肾癌(cbr)一线治疗中的应用:4年随访和非肾切除术患者(pts)亚组分析","authors":"L. Albiges, N. Tannir, M. Burotto, D. McDermott, E. Plimack, P. Barthélémy, C. Porta, T. Powles, F. Donskov, S. George, C. Kollmannsberger, H. Gurney, M. Grimm, Y. Tomita, D. Castellano, B. Rini, T. Choueiri, S. Shally Saggi, M. Mchenry, R. Motzer","doi":"10.1016/j.purol.2020.07.155","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":67244,"journal":{"name":"法国哲学研究","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés\",\"authors\":\"L. Albiges, N. Tannir, M. Burotto, D. McDermott, E. Plimack, P. Barthélémy, C. Porta, T. Powles, F. Donskov, S. George, C. Kollmannsberger, H. Gurney, M. Grimm, Y. Tomita, D. Castellano, B. Rini, T. Choueiri, S. Shally Saggi, M. Mchenry, R. Motzer\",\"doi\":\"10.1016/j.purol.2020.07.155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":67244,\"journal\":{\"name\":\"法国哲学研究\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"法国哲学研究\",\"FirstCategoryId\":\"1092\",\"ListUrlMain\":\"https://doi.org/10.1016/j.purol.2020.07.155\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"法国哲学研究","FirstCategoryId":"1092","ListUrlMain":"https://doi.org/10.1016/j.purol.2020.07.155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés